NEWS / Stock
Firms Reduce Access to Weight-Loss Drugs as Costs Mount
Milena Thomas
Published Jul 30, 2026
[tts_player]
Share:
Summary:
- According to Cigna Group, worries about persistent expenses are leading employers to scale back or drop coverage for weight-loss medications.
- Over 25% of large employers have already tightened utilization controls or plan to in 2027.
- Shares of Eli Lilly and Novo Nordisk declined after the announcement, with Lilly falling 3.8%.
Why Employers Are Pulling Back
After years of strong growth, the obesity drug market is now slowing as businesses and health insurers cut back on coverage, signaling a more cautious phase
Brian Evanko, Cigna’s CEO, said, “Cigna has stopped covering Wegovy and Zepbound for its own employees because of the cost.” An increasing number of large employers are adopting similar measures
Pharmaceutical companies are exploring various approaches to address the shortfall, such as conducting trials to demonstrate that these medications offer advantages beyond weight reduction, potentially increasing their appeal to insurance providers. However, businesses and insurance companies have strongly criticized the expense of providing these drugs over extended periods, causing some health plans to eliminate coverage or impose stricter access requirements for obesity treatments
This dynamic reflects a broader struggle between short-term budget constraints and potential long-term health savings. Drugmakers are seeking to prove that these medications reduce overall medical costs by preventing related conditions, while insurers and employers demand more concrete evidence before committing to expensive coverage
Get the market news that matters in a five-minute read with Market Briefs, our free daily newsletter
What the Numbers Show
A Mercer survey found that approximately 6% of large employers had discontinued coverage for weight-loss medications by 2026. An additional 5 percent indicated they intend to end coverage in 2027
Cigna CFO Ann Dennison stated that the company anticipates the deceleration in prescription growth for GLP-1 medications, including Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, will persist through the rest of the year
The decisions by employers and insurers come amid a broader debate about the long-term value of GLP-1 drugs. While these medications have shown significant benefits for weight loss and related conditions, their high list prices – often exceeding $1,000 per month – make them a major cost driver for health plans. Drugmakers like Novo Nordisk and Eli Lilly have faced pressure to justify the expense, and some have introduced patient assistance programs and employer discounts to maintain access. However, without clearer evidence that the drugs reduce overall healthcare spending, many companies remain hesitant to expand coverage.
What It Means for Your Portfolio
The remarks made by Cigna leaders regarding GLP-1 medication coverage and usage pertain to health plans that utilize the company’s pharmacy benefit manager, Express Scripts
Both Eli Lilly and Novo Nordisk currently provide substantial price reductions for patients who pay for the drugs themselves. Additionally, Lilly has introduced a recent initiative targeting specific employers, enabling them to obtain the medications at reduced rates
Evanko stated, “Should drug manufacturers decide to meaningfully discount the net prices they offer, we may revisit this in the future.”
The current pullback highlights the broader debate over how to manage the high upfront costs of these treatments against potential long-term health savings. Drugmakers continue to push for wider acceptance through additional clinical trials, while employers and insurers wait for clearer evidence of cost-effectiveness before expanding coverage again
Join Market Briefs, our free daily newsletter, for a quick daily rundown of the markets
Disclosure
Trending Briefs
U.S. Oil Refiners Post Unprecedented Gains as Global Fuel Stocks Dwindle
Jul 30, 2026
Google-Backed $15B Texas AI Hub for Anthropic with Morgan Stanley Lead
Jul 30, 2026
Jul 30, 2026
DeepSeek to Build 1-Gigawatt AI Data Hub in Inner Mongolia
Jul 30, 2026
Blackstone Acquires A$36B Australian Home Loan Portfolio from HSBC
Jul 30, 2026
Exelon Cuts Data Center Demand Forecasts Amid Growing Public Resistance
Jul 30, 2026
Firms Reduce Access to Weight-Loss Drugs as Costs Mount
Jul 30, 2026
Microsoft Stock Surges on Analyst’s AI Revenue Optimism
Jul 30, 2026
Ex-Qantas Executive Pursues American Capital for Budget Airline Zinc
Jul 30, 2026
Judge Lin Questions Government’s Justification for Anthropic AI Ban
Jul 30, 2026
Get Market Briefs every morning for free!
No fluff. No noise. No politics. Just finance news in 5 minutes.
Subscribe Free
